Malaria superbugs threaten global malaria control

February 1, 2017, Infectious Diseases Data Observatory
A thin-film Giemsa stained micrograph of ring-forms, and gametocytes of Plasmodium falciparum. Image: CDC

A lineage of multidrug resistant P. falciparum malaria superbugs has widely spread and is now established in parts of Thailand, Laos and Cambodia, causing high treatment failure rates for the main falciparum malaria medicines, artemisinin combination therapies (ACTs), according to a study published today in The Lancet Infectious Diseases.

The emergence and spread of artemisinin drug resistant P falciparum lineage represents a serious threat to global malaria control and eradication efforts. The authors warn that malaria parasites resistant to both artemisinin and its widely used partner drug piperaquine are now spreading quickly throughout Cambodia, with fitter multidrug resistant parasites spreading throughout western Cambodia, southern Laos and northeastern Thailand.

"We now see this very successful resistant parasite lineage emerging, outcompeting its peers, and spreading over a wide area. It has also picked up resistance to the partner drug piperaquine, causing high failure rates of the widely used artemisinin combination therapy DHA-piperaquine" says study lead author Prof. Arjen Dondorp, Head of Malaria and Deputy Head of the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Thailand, Asia. "We hope this evidence will be used to reemphasize the urgency of in the Asia-region before falciparum malaria becomes close to untreatable.

Noting that the further spread of these multidrug resistant parasites through India to sub-Saharan Africa would be a global public health disaster, the study authors call for accelerated efforts in the Greater Mekong Sub-region and closer collaboration to monitor any further spread in neighbouring regions.

"We are losing a dangerous race to eliminate artemisinin resistant falciparum malaria before widespread resistance to the partner antimalarials makes that impossible," said study contributor and Oxford and Mahidol University Prof Sir Nicholas White. "The consequences of resistance spreading further into India and Africa could be grave if drug resistance is not tackled from a global public health emergency perspective."

After examining blood spot samples from patients with uncomplicated falciparum malaria from sites in Cambodia, Laos, Thailand and Myanmar, the study team found that PfKelch13 C580Y, a single mutant parasite lineage, has spread across three countries, replacing parasites containing other, less ACT-resistant mutations. Although the C580Y mutation does not confer a higher level of artemisinin resistance than many other PfKelch13 mutations it appears to be fitter, more transmissible and spreading more widely.

"It isn't that the C580Y mutation itself makes the malaria parasites fitter, it is the other genetic changes that go along with it - hence the critical emphasis on the term "lineage". This is what makes superbugs - the evolution of multiple factors that make them fitter and more transmissible," explains Prof. Sir Nicholas White of Mahidol and Oxford Universities. "The spread and emergence of drug resistant malaria parasites across Asia into Africa has occurred before. Last time it killed millions. We need to work with our policy, research and funding partners to respond to this threat in Asia urgently to avoid history repeating itself."

Dr Mike Turner, Head of Infection and Immunobiology at Wellcome Trust concurs: "Already hundreds of thousands of people every year die from , including malaria. If nothing is done, this will increase to millions of people every year by 2050. The Oxford and Mahidol-led results show a worrying spread of parasite resistance. Data to help track resistance to drugs, such as this study, are vital for improving treatment, diagnosis and prevention of drug resistant infections."

Explore further: Two genetic markers that predict malaria treatment failure found

More information: The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong Subregion: a molecular epidemiology observational study, Lancet Infectious Diseases, dx.doi.org/10.1016/S1473-3099(17)30048-8

Related Stories

Two genetic markers that predict malaria treatment failure found

November 3, 2016
Scientists at the Wellcome Trust Sanger Institute and their collaborators have discovered genetic markers in malaria parasites linked with resistance to the anti-malarial drug piperaquine. Reported in Lancet Infectious Diseases, ...

Researchers identify genetic marker of resistance to key malaria drug

December 18, 2013
An international team of researchers has discovered a way to identify, at a molecular level, malaria-causing Plasmodium falciparum parasites that are resistant to artemisinin, the key drug for treating this disease. The research ...

Current malaria treatment fails in Cambodia due to drug-resistant parasites

January 7, 2016
New findings from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), confirm dihydroartemisinin-piperaquine, the first-line treatment for Plasmodium falciparum ...

Drug-resistant malaria strain contained in Asia: scientists

June 23, 2016
A parasite resistant to the top anti-malaria drug is confined to Southeast Asia and has not yet spread to sub-Saharan Africa as feared, said researchers Wednesday.

Study in Myanmar confirms artemisinin-resistant malaria close to border with India

February 19, 2015
The spread of malaria parasites that are resistant to the drug artemisinin - the frontline treatment against malaria infection - into neighbouring India would pose a serious threat to the global control and eradication of ...

Drug-resistant malaria could spread to Africa: study

October 20, 2015
A drug-resistant malaria parasite from southeast Asia can infect African mosquitoes, said a study Tuesday, boosting fears that a hard-to-cure variant of the disease could reach the world's most vulnerable continent.

Recommended for you

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

Flu shot only 36 percent effective, making bad year worse (Update)

February 15, 2018
The flu vaccine is doing a poor job protecting older Americans and others against the bug that's causing most illnesses.

IFN-mediated immunity to influenza A virus infection influenced by RIPK3 protein

February 15, 2018
Each year, influenza kills half a million people globally with the elderly and very young most often the victims. In fact, the Centers for Disease Control and Prevention reported 37 children have died in the United States ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.